Close Menu


By Julia Karow GnuBio plans to release a beta version of its desktop microfluidic sequencer in the second quarter and to launch the system commercially by the end of the year, the company said earlier this month.

By Justin Petrone
The Singapore Institute of Manufacturing Technology has established a new resource to help companies develop microfluidic devices, including biochips.

Under the cross- and sub-licensing deals, Fluidigm gains access to PCR-related patents from Life Tech, which in return receives access to imaging readers and other technologies from Fluidigm.

The company has sequenced amplicons from plasmids as well as from clinical targets, including a 477-base amplicon from the p53 gene.

An Access Array protocol for the Ion Torrent PGM is currently in beta testing, while the company has established "strong proof of principle" for its MiSeq protocol.

The Harvard University spinout also disclosed that it raised $8 million in private financing last year. It is working on a fast and scalable microfluidics-based sequencing platform priced at less than $50,000 that will allow users to analyze target genes in a single or a thousand samples at the same cost per sample.

The investment firm gave Fluidigm an "Outperform" rating and a valuation of between $17 and $18.

GenMark sued Caliper in November as a preemptive strike after Caliper had told GenMark that it was infringing on three of its patents. GenMark sought a finding that there was no infringement.


As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.

BBC News says the uncertainty over Brexit is affecting science funding in the UK.

A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.

In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.